Biofrontera received patent approval for the revised formulation of Ameluz ® in April 2025, extending patent protection through to December 2043. The Orange Book is published by the U.S. Food and Drug ...
WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results